Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Titel:
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Auteur:
Schwartz, Gregory G. Bessac, Laurence Berdan, Lisa G. Bhatt, Deepak L. Bittner, Vera Diaz, Rafael Goodman, Shaun G. Hanotin, Corinne Harrington, Robert A. Jukema, J. Wouter Mahaffey, Kenneth W. Moryusef, Angèle Pordy, Robert Roe, Matthew T. Rorick, Tyrus Sasiela, William J. Shirodaria, Cheerag Szarek, Michael Tamby, Jean-François Tricoci, Pierluigi White, Harvey Zeiher, Andreas Steg, Philippe Gabriel